TX-EAGLE-EYE-NETWORKS
30.9.2021 13:02:11 CEST | Business Wire | Press release
Eagle Eye Networks, the global leader in cloud video surveillance, today announced the acquisition of artificial intelligence leader Uncanny Vision, accelerating the company’s leadership in providing AI and analytics to make customers’ businesses more efficient and the world a safer place. The acquisition also includes research and development capabilities and a new regional office in Bangalore, India.
“After evaluating more than a dozen AI companies, we began working with Uncanny Vision in 2020. It didn’t take long for us to conclude that Uncanny Vision is the clear leader in surveillance AI,” said Dean Drako, Eagle Eye Networks CEO. “Their award-winning AI technology is deployed across thousands of locations, including Fortune 500 customers.”
The deal accelerates Eagle Eye’s plan, announced in November 2020 , when Eagle Eye raised funds from venture capital firm Accel, to dramatically reshape video surveillance.
Uncanny Vision’s deep learning algorithms enable recognition, identification, and prediction, improving business operations, customer service, and site safety. Uncanny Vision’s award-winning AI is used today in multiple applications, including:
- Smart parking
- Retail analytics
- Gate security
- Toll automation
- Smart cities
- ATM monitoring
- Worker safety
- Perimeter security
Drako said, “Uncanny Vision’s tools for training, building, and optimizing models, and its infrastructure for managing and storing training data are superior. This is a key component we’re excited to add to the Eagle Eye Networks platform.”
All 60 Uncanny Vision employees will be retained, and Eagle Eye plans to expand the Bangalore office. Eagle Eye is committed to supporting Uncanny Vision’s current customers, and will continue to build its global infrastructure to provide the very best 24/7 support to its valued customers around the world.
Uncanny Vision co-founders, Ranjith Parakkal and Navaneethan Sundaramoorthy, have joined the Eagle Eye leadership team. Parakkal said, “We share the Eagle Eye team’s vision to deliver advanced, cyber secure AI cloud video surveillance offerings that transform video surveillance for businesses around the globe.”
"The economic model of delivering subscription-based AI on a per-camera basis through a global cloud infrastructure will ignite growth for security integrators who are otherwise challenged with how to build a financially stable business," said Alper Cetingok, Managing Director and Head of the Security & Safety Practice at Raymond James.[1]
ABOUT EAGLE EYE NETWORKS
Eagle Eye Networks is No. 1 in cloud video surveillance worldwide. Our 100% cloud managed solutions provide cloud and on-premises recording, bank-level security and encryption, and broad analog and digital camera support – all accessed via the web or mobile applications. Eagle Eye Networks delivers cyber secure cloud-based video with artificial intelligence (AI) and analytics to make businesses more efficient and the world a safer place. All products benefit from Eagle Eye’s developer friendly RESTful API platform and Big Data Video FrameworkTM . Headquartered in Austin, Texas, Eagle Eye has offices in Bangalore, Tokyo, and Amsterdam. For more information, visit www.een.com .
ABOUT UNCANNY VISION
Founded in 2013, Uncanny Vision is an award-winning AI-based computer vision company delivering next generation intelligent surveillance solutions for smart cities, smart buildings and infrastructure specifically for people and vehicle monitoring using cameras. Uncanny Vision surveillance enables cameras to "see" and "understand" their environment instantly, using optimized real-time AI/deep learning algorithms. For more information, visit www.uncannyvision.com .
[1] Raymond James & Associates was not a party to the transaction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005143/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom